Taken together, our results indicate that the intravenously delivered hAT-MSCs exhibit a dose-dependent efficacy against Df-induced AD in both criteria of gross and histopathological evaluation, and that mechanisms regulating IgE production might be involved in this effect. Here, IGHE is linked to Alzheimer disease.